| Business Summary | | BioCoral,
Inc.
is
an
international
biotechnology
company
specializing
in
research,
development
and
commercialization
of
patented
high
biotech
technologies
and
biomaterials
in
the
health
care
area.
Through
its
subsidiaries,
the
Company
researches,
develops,
manufactures
and
markets
bone
graft
substitute
and
other
high
tech
patented
biomaterials
in
a
number
of
countries
outside
the
United
States.
The
Company
has
developed
what
management
believes
is
the
world's
first
fully
autologous
fibrin
glue. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | BioCoral,
Inc.
is
primarily
engaged
in
developing,
manufacturing
and
marketing
bone
graft
and
growth
material
for
orthopedic,
oral
and
maxillofacial
applications.
For
the
six
months
ended
6/30/01,
total
revenues
fell
19%
to
$181
thousand.
Net
loss
totalled
$1.2
million,
up
from
$424
thousand.
Revenues
reflect
a
decrease
in
Inoteb's
sales.
Higher
loss
reflects
increased
interest
expense
including
a
charge
for
beneficial
conversion
rights. | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Nasser Nassiri, 36 | Chairman,
Pres and CEO | Yuhko Grossmann, 35 | Sec.,
Treasurer, Director |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|